文献速递肿瘤 PET/CT神经核医学

肺神经内分泌肿瘤生长抑素受体PET/CT影像特征与免疫组化相关性:一项回顾性观察研究

Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-06-08

该回顾性研究纳入32例确诊肺神经内分泌肿瘤患者,分析生长抑素受体(SSTR)PET/CT影像特征与SSTR2、SSTR5及Ki-67免疫组化指标的相关性。结果显示SSTR2免疫组化与SSTR-PET/CT总体一致率为75.0%(p=0.003),SUVmax与SSTR2免疫组化评分显著相关(p=0.002)。作者认为在无法进行SSTR-PET/CT时,SSTR2免疫组化或可作为替代指标用于部分患者的临床决策。

要点

  • SSTR2免疫组化与SSTR-PET/CT一致率为75.0%(24/32,p=0.003)。
  • SSTR-PET/CT的SUVmax与SSTR2免疫组化评分显著相关(p=0.002)。
  • 作者认为SSTR2免疫组化或可在无法进行SSTR-PET/CT时替代其用于临床决策。

核心结论

  • 该回顾性研究显示肺神经内分泌肿瘤中SSTR2免疫组化与SSTR-PET/CT肿瘤摄取总体一致性良好。
  • SSTR-PET/CT的SUVmax值可作为SSTR2密度的参数。
  • 在相对较小队列的限制下,作者认为SSTR2免疫组化或可在无法进行SSTR-PET/CT时替代其用于部分肺神经内分泌肿瘤患者的临床决策。

研究设计与样本

  • 回顾性观察研究,纳入2011年7月至2020年3月间因肺神经内分泌肿瘤行68Ga-DOTA-生长抑素类似物SSTR-PET/CT的551例患者中的32例确诊神经内分泌肿瘤患者。
  • 其中14例有18F-FDG-PET/CT资料;PET/CT图像行定性及半定量分析,并评估SSTR2、SSTR5及Ki-67免疫组化。
  • 统计分析包括kappa统计和Spearman秩相关检验。

主要发现

  • 最终诊断包括26例典型类癌-G1和6例非典型类癌-G2。
  • SSTR2免疫组化阳性率为62.5%,SSTR5免疫组化阳性率为19.4%。
  • SSTR2免疫组化与SSTR-PET/CT相关见于24/32例(75.0%,p=0.003):其中20例一致阳性,4例一致阴性。
  • 免疫组化阳性时与SSTR-PET/CT一致(均阳性)为100%,免疫组化阴性时一致(均阴性)为33.3%。
  • 8例免疫组化阴性而SSTR-PET/CT阳性,除1例外均为低级别摄取。

关键数值与推荐

  • SSTR2免疫组化阳性率62.5%,SSTR5免疫组化阳性率19.4%。
  • SSTR2免疫组化与SSTR-PET/CT一致率75.0%(24/32,p=0.003)。
  • 免疫组化阳性时与SSTR-PET/CT一致率100%,免疫组化阴性时一致率33.3%。
  • SUVmax与SSTR2免疫组化评分相关(p=0.002)。

临床怎么用

  • 作者认为在无法进行SSTR-PET/CT时,SSTR2免疫组化或可作为替代指标用于部分肺神经内分泌肿瘤患者的临床决策。
  • SSTR-PET/CT的SUVmax值可作为SSTR2密度的参数。

局限性

  • 原文指出研究为回顾性研究。
  • 原文指出队列相对较小。
  • 作者在结论中写明其数据是在相对较小队列的限制下提出的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To correlate somatostatin receptor (SSTR) and proliferative activity profile (SSTR2, SSTR5, Ki-67) at immunohistochemistry (IHC) with SSTR-PET/CT imaging features in a retrospective series of lung neuroendocrine tumors (NET). Proliferative activity by Ki-67 and 18F-FDG-PET/CT parameters (when available) were also correlated. METHODS: Among 551 patients who underwent SSTR-PET/CT with 68Ga-DOTA-somatostatin analogs (SSA) between July 2011 and March 2020 for lung neuroendocrine neoplasms, 32 patients with a confirmed diagnosis of NET were included. For 14 of them, 18F-FDG-PET/CT was available. PET/CT images were reviewed by qualitative and semi-quantitative analyses. Immunohistochemistry for SSTR2, SSTR5, and Ki-67 was assessed. Inferential analysis was performed including kappa statistics and Spearman's rank correlation test. RESULTS: Definitive diagnosis consisted of 26 typical carcinoids-G1 and six atypical carcinoids-G2. Positive SSTR2-IHC was found in 62.5% of samples while SSTR5-IHC positivity was 19.4%. A correlation between SSTR2-IHC and SSTR-PET/CT was found in 24/32 cases (75.0%, p = 0.003): 20 were concordantly positive, 4 concordantly negative. For positive IHC, 100% concordance with SSTR-PET/CT (both positive) was observed, while for negative IHC concordance (both negative) was 33.3%. In 8 cases, IHC was negative while SSTR-PET/CT was positive, even though with low-grade uptake in all but one. A significant correlation between SUVmax values at SSTR-PET/CT and the SSTR2-IHC scores was found, with low SUVmax values corresponding to negative IHC and higher SUVmax values to positive IHC (p = 0.002). CONCLUSION: This retrospective study showed an overall good agreement between SSTR2-IHC and tumor uptake at SSTR-PET/CT in lung NETs. SSTR-PET/CT SUVmax values can be used as a parameter of SSTR2 density. Within the limits imposed by the relatively small cohort, our data suggest that SSTR2-IHC may surrogate SSTR-PET/CT in selected lung NET patients for clinical decision making when SSTR-PET/CT is not available.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rufini V, Lorusso M, Inzani F, et al. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. Eur J Nucl Med Mol Imaging. 2022. PMID: 35674739. doi:10.1007/s00259-022-05848-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。